NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by BTIG Research in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 191.55% from the company’s current price.

NRXP has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. D. Boral Capital reiterated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 10th. Finally, Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Stock Performance

NRXP opened at $3.43 on Tuesday. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The stock has a market capitalization of $124.27 million, a PE ratio of -6.24 and a beta of 2.18. The stock’s 50 day moving average price is $3.78 and its 200-day moving average price is $2.97.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. Research analysts forecast that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ethos Financial Group LLC boosted its holdings in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares in the last quarter. AdvisorShares Investments LLC increased its holdings in shares of NRx Pharmaceuticals by 28.2% during the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares in the last quarter. Anson Funds Management LP increased its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares in the last quarter. State Street Corp raised its position in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth about $994,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.